271 related articles for article (PubMed ID: 32388280)
1. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
2. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
3. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
4. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
[TBL] [Abstract][Full Text] [Related]
5. A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).
Papakonstantinou E; Vlachakis D; Thireou T; Vlachoyiannopoulos PG; Eliopoulos E
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805725
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.
Guan X; Bryniarski MA; Morris ME
AAPS J; 2018 Nov; 21(1):3. PubMed ID: 30397860
[TBL] [Abstract][Full Text] [Related]
7. Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: Feeding Warburg's sweet tooth and blocking acid export as an anticancer strategy.
Pivovarova AI; MacGregor GG
Biomed Pharmacother; 2018 Feb; 98():173-179. PubMed ID: 29253765
[TBL] [Abstract][Full Text] [Related]
8. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity.
Nancolas B; Sessions RB; Halestrap AP
Biochem J; 2015 Feb; 466(1):177-88. PubMed ID: 25437897
[TBL] [Abstract][Full Text] [Related]
9. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
12. Treatment of
Follman KE; Morris ME
J Pharmacol Exp Ther; 2019 Jul; 370(1):84-91. PubMed ID: 31010842
[TBL] [Abstract][Full Text] [Related]
13. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.
Ovens MJ; Davies AJ; Wilson MC; Murray CM; Halestrap AP
Biochem J; 2010 Jan; 425(3):523-30. PubMed ID: 19929853
[TBL] [Abstract][Full Text] [Related]
14.
Rodriguez-Cruz V; Morris ME
J Pharmacol Exp Ther; 2021 Jul; 378(1):42-50. PubMed ID: 33963018
[TBL] [Abstract][Full Text] [Related]
15. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates.
Wang N; Jiang X; Zhang S; Zhu A; Yuan Y; Xu H; Lei J; Yan C
Cell; 2021 Jan; 184(2):370-383.e13. PubMed ID: 33333023
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1.
Wang Y; Qin L; Chen W; Chen Q; Sun J; Wang G
Eur J Med Chem; 2021 Dec; 226():113806. PubMed ID: 34517305
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
20. A Nonradioactive High-Throughput Screening-Compatible Cell-Based Assay to Identify Inhibitors of the Monocarboxylate Transporter Protein 1.
Bailey TL; Nieto A; McDonald PH
Assay Drug Dev Technol; 2019 Aug; 17(6):275-284. PubMed ID: 31532712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
